The clinician who is called upon to treat an injured person is always confronted with the problem of specific prophylaxis against tetanus, a disease of extreme rarity but one of extreme severity should it occur. It is the latter consideration which usually dictates the management of a case, and, as a result, passive immunization with equine tetanus antitoxin is used far more often than would appear necessary or desirable. If this form of prophylaxis carried no complications then there would be little point in questioning its widespread use, but the sequelae of antiserum therapy are frequent and often disabling. Indeed, a special committee of the London Academy of Medicine, Ontario, recommended mass immunization with tetanus toxoid not to reduce the incidence of tetanus, which was negligible, but to lower the morbidity and mortality of tetanus antitoxin allergy, which was considerable (Toogood, 1960) . From a review of recent papers we believe that 5-6 % of persons receiving horse serum will exhibit post-injectional complications of varying severity. It is therefore understandable that there is a great reluctance to administer heterologous serum in tetanus prophylaxis.
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The idea of using homologous human antitoxin has been suggested by some workers (Turner, Stafford, and Goldman, 1954; Smolens, Stokes, and Vogt, 1957; Stafford, 1960) but in the absence of any information on the dosage and the duration of passive immunity homologous serum has never been seriously considered. In an earlier study (Suri and Rubbo, 1961) it was shown by animal experiment that homologous serum was at least one hundred times more effective than the heterologous type. Further, it was found that a dose of 200 units of homologous antitoxin produced serum levels of 0.02 unit/ml. in five out of seven persons for at least 21 days. This concentration of antitoxin, if maintained throughout the incubation period, has been estimated by Bruce (1920) All volunteers were bled (approximately 15 ml. of blood was taken) before immunization and at weekly intervals for three weeks. The antitoxin content of the sera was determined by mouse-protection tests using three mice for each serum dilution as previously described (Suri and Rubbo, 1961) .
Results
In Table I the antitoxin levels for the 33 subjects are listed. The figures show remarkably little variation between different individuals receiving the same dose of antitoxin and the rate of disappearance in each dose group follows a straight-line curve. The constancy of antitoxin level and its slow die-away rate contrasts strongly with the variability found in passive immunization with heterologous serum. The only discrepancy, which was consistently observed, was the lower levels exhibited by the Indian subjects when compared with Europeans receiving the same dose of antitoxin-namely, 10 units/kg. of body weight. This curious difference is discussed later.
When the averages of the titrations are graphed (Fig.  1 ) the curves fall neatly into place in respect to dosage, and the disappearance rate is slow but constant. The Indian subjects (Fig. 2) appear to eliminate the antitoxin more rapidly, and this is consistent with the lower antitoxin levels found at the first and subsequent bleedings. In general, however, these results closely confirm our previous titrations and provide a basis for discussion of the value of human immune globulin in tetanus prophylaxis. In the concentration of circulating antitoxin is predictably constant when it is used to induce passive immunity (Table I) , whereas with heterologous serum antitoxin levels are variable (Suri and Rubbo, 1961) . Thirdly, in contrast to heterologous antitoxin, homologous serum gives protective and persistently high levels of circulating antitoxin at much lower doses than is possible with heterologous serum. These points are now discussed in more detail.
A direct comparison of circulating antitoxin levels after passive immunization with the two types of sera has not been possible. Mainly because of ethical reasons we did not feel justified in subjecting nonimmune individuals to the risk of sensitization with equine serum. However, when the results of our previous work are compared with those reported here it is immediately obvious that a fourfold higher dose of heterologous serum fails to produce consistently a protective level of circulating antitoxin (see below) as is observed with the homologous immune globulin. The differences are shown in Table II , in which it is interesting to note that 15% of the subjects receiving the equine serum had serum antitoxin levels less than 0.05 unit/ml. seven days after immunization. Variations of this type might explain the apparent failure of heterologous serum in prophylaxis and the tendency in some quarters to recommend doses as high as 3,000 units. (1961) have carried out a similar study on the persistence of horse and human tetanus antitoxins. The general trend of their results is similar to those reported here. They showed that homologous antitoxin persisted at higher levels and for a much longer period of time than the heterologous serum. Unfortunately, we cannot compare our results with theirs, since the dose of human antitoxin they used was not clearly defined-it contained at least 500 units and less than 1,000 units/ml.
Whether a dose of 400 units of antitoxin will interfere with primary immune response of toxoid when given simultaneously has yet to be answered. In our earlier study we were able to show that the primary immune response to toxoid in combined active and passive immunization was best expressed by delaying the injection of toxoid for seven days or reducing the dose of antitoxin. With heterologous serum reducing the dose is contraindicated, but with homologous globulin this can be achieved without loss of passive protection. While we do not think a combined active-passive immunization treatment using 0.5 ml. of adsorbed toxoid and 400 units of human immune globulin would interfere with the primary immune response, this point will have to be established by experiment. This is now being investigated.
Finally, the question of cost and availability of immune globulin arises. This is really outside the scope of the present discussion. We realize that it could not replace equine serum on the scale at which the latter is now used, even though a much lower dosage is required. On the other hand, one might question the justification for the widespread use of passive immunization and suggest that more selective criteria should be considered. If the indications for passive immunization were based on clinical and epidemiological evidence rather than on medico-legal grounds, it is not improbable that the demand for tetanus antitoxin in general would be considerably reduced, in which case the supply of human immune globulin might come nearer to meeting the demand. For the present, however, the product should be offered at the doses recommended to all persons requiring passive immunization who are known to be hypersensitive to horse serum.
The curious but consistent difference of antitoxin levels between European and Indian subjects receiving the same dose of immune globulin must be investigated more thoroughly. At the moment we can only speculate on the reasons for the difference. For instance, the globulin used in this study was derived from Europeans, and it is possible that it is "slightly foreign" to the Indian subject and hence destroyed more rapidly. Or the protein turnover might be higher in the Indian subject because of the vast difference in protein content of the diet in the two racial groups. The phenomenon seems worthy of a more detailed investigation. These differences, however, do not detract from our demonstration that a low dose of human immune globulin is vastly superior in passive immunization against tetanus than a high sensitizing dose of horse serum. Summary Twenty-seven non-immune European adults and six Indians were passively immunized with tetanus antitoxin, which was given as gamma-globulin prepared from actively immunized Europeans. Titration of tetanus antitoxin in the serum of these persons was done before and 7, 14, and 21 days after immunization. The results showed that high antitoxin levels could be obtained with relatively low doses and that, in contrast to equine antitoxin immunization, the rate of disappearance of antitoxin was slow. However, the Indian subjects appeared to eliminate the immune globulin more rapidly than Europeans receiving the same dose.
The question of passive immunization using homologous antitoxin has been discussed. It Dr. Sergent's work which had proved the role of the louse as a carrier of disease, his research on the transmission of oriental sore by sandflies and his discovery that debab, the principal malady affecting camels, is caused by a trypanosome. Most, however, were familiar with his name as the originator, together with his brother Etienne Sergent, of the theory of premunition which opened up new vistas in the field of immunology. The Manson Medal is a personal award, but the President stated that he wished, on behalf of the Society, " to take this opportunity of paying tribute to France which has played such an important part in the advance of tropical medicine-in the torrid zone as a whole and in Africa in particular." Especially, he stated, " must we honour the self-sacrificing work done by generation after generation of Frenchmen in Algeria-many of them born there-commencing on the never-to-be-forgotten day, November 6, 1880, when Laveran, with the French Army in Constantine, discovered the first malaria parasite. Since that day the French in Algeria have laboured without cessation to better the lot of man and animal in Africa, and the Pasteur Institute of Algiers has shone like a beacon over darkest Africa."
